Assess therapeutic response through PD-LI testing

Immunotherapies have recently emerged as a therapeutic option for patients with non-small cell lung cancer (NSCLC). Therapies have been approved for both first- and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression.

Immunotherapy test menu


Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific therapies. The specific PD-L1 clone, scoring method, and eligibility requirements depend on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor under consideration.

The FDA List of Cleared or Approved Companion Diagnostic Devices is frequently updated and provides current guidance for treatment indications and scoring.

Key testing


Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.